| Recruiting | OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma NCT07089940 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Withdrawn | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Col NCT06626256 | City of Hope Medical Center | Phase 1 |
| Withdrawn | FL118 for Treating Patients With Advanced Pancreatic Ductal Adenocarcinoma NCT06206876 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced NCT06906562 | Sameek Roychowdhury | Phase 2 |
| Recruiting | Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer NCT06958328 | NRG Oncology | Phase 3 |
| Recruiting | Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally A NCT06381154 | Mayo Clinic | Phase 2 |
| Recruiting | Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline NCT06423326 | Emory University | Phase 2 |
| Withdrawn | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-adva NCT06398587 | OHSU Knight Cancer Institute | Phase 2 |
| Recruiting | Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, NCT05911243 | University of Washington | N/A |
| Recruiting | Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advan NCT05411094 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Withdrawn | SMMART Adaptive Clinical Treatment (ACT) Trial NCT05238831 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Recruiting | Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors NCT05053971 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Active Not Recruiting | Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer NCT05034627 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer NCT04821284 | Flemming Forsberg | Phase 1 / Phase 2 |
| Active Not Recruiting | A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer NCT05055323 | Thomas Jefferson University | Phase 1 |
| Recruiting | Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancre NCT04887805 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Trea NCT04616534 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations NCT04550494 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma NCT04111172 | Thomas Jefferson University | Phase 2 |
| Withdrawn | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumor NCT03925428 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study NCT04449679 | Thomas Jefferson University | N/A |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Active Not Recruiting | Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine NCT03816358 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Losartan and Hypofractionated Rx After Chemo for Tx of Borderline Resectable or Locally Advanced Unresectable NCT04106856 | University of Utah | Phase 1 |
| Recruiting | Targeted Pathway Inhibition in Patients With Pancreatic Cancer NCT04005690 | OHSU Knight Cancer Institute | EARLY_Phase 1 |
| Withdrawn | Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer NCT03432676 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Phase I Study of SOR-C13 in Patients With Advanced Solid Tumors NCT03784677 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | IACS-010759 in Advanced Cancers NCT03291938 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors o NCT03033225 | Mayo Clinic | Phase 2 |
| Active Not Recruiting | Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung C NCT02983578 | M.D. Anderson Cancer Center | Phase 2 |